Navigation Links
New data showed Actos prevented progression of atherosclerotic plaque volume in patients
Date:3/31/2008

Chicago, IL, March 31, 2008 New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS® (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline. These data stem from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial.

The PERISCOPE trial was presented today as a late breaker at the 57th Annual Scientific Session of the American College of Cardiology in Chicago. This trial adds to the body of cardiovascular data for ACTOS. ACTOS studies, conducted over the past 10 years in more than 16,000 patients, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

We are pleased with the results of the PERISCOPE, which further expands our cardiovascular data with ACTOS, said David P. Recker, M.D., senior vice president, Clinical Sciences and interim president at Takeda Global Research & Development. While not definitive, data from PERISCOPE combined with results from a previous study, looking at surrogate endpoints, have shown a consistent trend toward decreasing cardiovascular risk by reducing the atherosclerotic burden in people with type 2 diabetes.

PERISCOPE is the first clinical trial to examine the effects of an oral antidiabetic medication on the development of coronary atherosclerosis in patients with type 2 diabetes using IVUS technology. The trial conducted in 97 centers in the U.S., Canada and Latin America with 543 patients, used IVUS imaging of the coronary arteries. The analysis demonstrated a statistically significant difference in percent change in coronary artery atheroma volume in favor of ACTOS treatment compared to glimepiride t
'/>"/>

Contact: Amy Losak
amy.losak@ketchum.com
917-865-6688
Takeda Pharmaceuticals North America
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
2. Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
3. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
4. New study of Concerta showed significant improvement of ADHD symptom management in adults
5. African Americans at Risk for Low Calcium Intake - New Survey Finds Those Experiencing Symptoms of Lactose Intolerance May be Sidelining Dairy in Their Diets
6. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
7. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
8. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
9. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
10. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
11. One third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Everett, WA (PRWEB) August 01, 2014 ... a problem throughout your entire home.“ In a newly ... Space or Attic Insulation Needs To Be Replaced ,” ... has deteriorated, become damp, or been infested by critters. ... space cleaning quote from Clean Crawls - http://www.cleancrawl.com/contact ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The Multiple System ... to serving patients, caregivers and families affected by the neurological ... Kramer Sutton of La Coste, TX to its Board of ... of 39 years, Eric Sutton. He was diagnosed officially with ... at home with his family. Like many others with this ...
(Date:8/1/2014)... 01, 2014 Narrow networks that ... and employers effective options to trim pharmacy costs ... that they can enhance formulary compliance and achieve ... report that nearly all PBMs now include a ... proposals. The Aug. 12 webinar from Atlantic ...
(Date:8/1/2014)... 01, 2014 Millions of women suffer ... legs and in some cases the arms, causing an ... about 17 million women in the U.S. alone are ... with the pain, embarrassment and discomfort caused by lipedema, ... physicians are unaware that this is a disease,” says Dr. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Get the ... partnership with PitchBook presents the 3Q 2014 Private Equity ... private equity investment, exits and fundraising activity in the ... to help plan for private equity endeavors for the ... form to download it now. , About Merrill DataSite ...
Breaking Medicine News(10 mins):Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 3Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2
... Nov. 21 Inverness Medical,Innovations, Inc. (Amex: IMA ... offering on Tuesday. The Company sold a total,of 13,634,302 ... of $61.49,per share. The total number of shares sold ... upon their exercise of their,over-allotment option in full. Certain ...
... The precise tailoring of tumor target treatment for patients ... to only administer treatments that have a high probability ... on imaging technologies, which are used to detect tumors ... guide therapy or surgery. , Vascular endothelial growth ...
... arterial vascular disease is widespread and often deadly among ... and treat it, according to a new report by ... Medical Center and Weill Cornell Medical College campuses of ... the fact that for years, cardiovascular research has focused ...
... Portable M5 Diagnostic Imaging Systems, SHENZHEN, China, ... MR ), a leading developer, manufacturer,and marketer ... growing,international presence, today announced that it will attend ... in Chicago,Illinois at the McCormick Place from November ...
... 21 Genomic Health,Inc. (Nasdaq: GHDX ) ... and Chief Executive Officer, will present at the ... on November 28, 2007 at 1:00,p.m. Eastern Time., ... webcast of the,presentation, visit the Investor Relations section ...
... Eclipsys Corporation(R),(Nasdaq: ECLP ), The Outcomes ... Merrill Lynch Health Services Investor Conference,taking place next ... http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), Eclipsys executives will present ... a.m. Eastern time. Interested parties are invited to,listen ...
Cached Medicine News:Health News:Inverness Medical Innovations Announces Closing of Public Offering 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 3Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 4Health News:Mindray to Attend 2007 RSNA Conference in Chicago 2Health News:Mindray to Attend 2007 RSNA Conference in Chicago 3Health News:Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 3
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... Nektar Therapeutics (Nasdaq: NKTR ) today reported its ... Cash and investments in marketable securities at ... million at March 31, 2014."The second half of 2014 will ... to significant milestones for a number of our late-stage clinical ... of Nektar. "The first of these is the potential US ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
A sturdy, robust stool. Gas operated height adjustment for convenience....
Lacrimal Cannulas, 19 g. shaft tapering to 23 g. cannula, straight. Overall length 37.5 mm. 5/box....
Viscoelastic Cannula, 27 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 27 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box....
Medicine Products: